StockData
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc. (KPTIQ) stock

KPTIQOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as KPTI
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 1/30
Share price
Not available yet

Price, market cap and P/E appear here once daily prices are connected.

Karyopharm Therapeutics cash

Cash and short-term investments held at the end of each period.

Karyopharm Therapeutics's cash was $65.10M at Jun 30, 2026. For fiscal 2025 it was $63.70M, down 41.6% from the year before. Over ten years it grew -9.7% a year on average. The highest annual figure on record is $328.92M in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$63.70M-41.6%
FY2024Dec 31, 2024$109.05M-43.0%
FY2023Dec 31, 2023$191.44M-31.5%
FY2022Dec 31, 2022$279.66M+18.7%
FY2021Dec 31, 2021$235.60M-6.7%
FY2020Dec 31, 2020$252.44M-4.3%
FY2019Dec 31, 2019$263.79M-19.8%
FY2018Dec 31, 2018$328.92M+123.8%
FY2017Dec 31, 2017$146.96M+13.0%
FY2016Dec 31, 2016$130.03M-26.2%
FY2015Dec 31, 2015$176.12M-14.4%
FY2014Dec 31, 2014$205.72M+31.9%
FY2013Dec 31, 2013$155.97M+39791.0%
FY2012Dec 31, 2012$391.00K-94.0%
FY2011Dec 31, 2011$6.51M+89.0%
FY2010Dec 31, 2010$3.45M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$65.10M+25.9%
Q1 FY2026Mar 31, 2026$90.90M+30.0%
Q4 FY2025Dec 31, 2025$63.70M-41.6%
Q3 FY2025Sep 30, 2025$45.90M-65.6%
Q2 FY2025Jun 30, 2025$51.70M-66.0%
Q1 FY2025Mar 31, 2025$69.90M-53.0%
Q4 FY2024Dec 31, 2024$109.05M-43.0%
Q3 FY2024Sep 30, 2024$133.50M-35.9%
Q2 FY2024Jun 30, 2024$152.12M-35.7%
Q1 FY2024Mar 31, 2024$148.58M-42.9%
Q4 FY2023Dec 31, 2023$191.44M-31.5%
Q3 FY2023Sep 30, 2023$208.32M+40.4%
Q2 FY2023Jun 30, 2023$236.77M+38.6%
Q1 FY2023Mar 31, 2023$260.38M+26.8%
Q4 FY2022Dec 31, 2022$279.66M+18.7%
Q3 FY2022Sep 30, 2022$148.38M-27.3%
Q2 FY2022Jun 30, 2022$170.85M-27.6%
Q1 FY2022Mar 31, 2022$205.31M-8.5%
Q4 FY2021Dec 31, 2021$235.60M-6.7%
Q3 FY2021Sep 30, 2021$204.21M-22.4%
Q2 FY2021Jun 30, 2021$235.89M-20.5%
Q1 FY2021Mar 31, 2021$224.37M-36.3%
Q4 FY2020Dec 31, 2020$252.44M-4.3%
Q3 FY2020Sep 30, 2020$263.04M-1.7%
Q2 FY2020Jun 30, 2020$296.72M+36.6%
Q1 FY2020Mar 31, 2020$352.13M+33.2%
Q4 FY2019Dec 31, 2019$263.79M-19.8%
Q3 FY2019Sep 30, 2019$267.53M+29.4%
Q2 FY2019Jun 30, 2019$217.16M-9.9%
Q1 FY2019Mar 31, 2019$264.42M+102.0%
Q4 FY2018Dec 31, 2018$328.92M+123.8%
Q3 FY2018Sep 30, 2018$206.77M+73.2%
Q2 FY2018Jun 30, 2018$241.12M+68.1%
Q1 FY2018Mar 31, 2018$130.92M+18.6%
Q4 FY2017Dec 31, 2017$146.96M+13.0%
Q3 FY2017Sep 30, 2017$119.41M-5.8%
Q2 FY2017Jun 30, 2017$143.45M–
Q1 FY2017Mar 31, 2017$110.36M–
Q4 FY2016Dec 31, 2016$130.03M–
Q3 FY2016Sep 30, 2016$126.81M–

More Karyopharm Therapeutics figures

See a number that looks wrong?